Olamufloxacin methanesulfonate  (Synonyms: HSR-903)

Olamufloxacin (HSR-903) methanesulfonate is an orally active fluoroquinolone antibacterial agent. Olamufloxacin methanesulfonate inhibits DNA supercoiling activity. Olamufloxacin methanesulfonate exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin methanesulfonate can be used for the research of bacterial infections^{[1][2][3][4][5]}.

Olamufloxacin methanesulfonate demonstrates potent antimicrobial activity against Gram-positive and Gram-negative clinical bacterial isolates, with MIC₅₀-like MICs ranging from 0.008 mg/L to 0.25 mg/L depending on the strain^[1].
Olamufloxacin (18-42 h) methanesulfonate potently inhibits growth of gram-positive bacterial clinical isolates including MSSA (MIC₉₀ = 0.78 μg/mL), MRSA (MIC₉₀ = 1.56 μg/mL), PSSP (MIC₉₀ = 0.05 μg/mL), and PRSP (MIC₉₀ = 0.05 μg/mL)^[2].
Olamufloxacin (1/4×-2× MIC; 4 h) methanesulfonate demonstrates rapid bactericidal activity against S. aureus Smith, E. coli KC-14, and P. aeruginosa E-2^[2].
Olamufloxacin methanesulfonate potently inhibits E. coli KL-16 DNA gyrase (IC₅₀ = 0.74 μg/mL) but shows weak activity against human placental topoisomerase II (IC₅₀ = 786 μg/mL)^[2].
Olamufloxacin (48-72 h) methanesulfonate potently inhibits growth of Chlamydia psittaci, Chlamydia trachomatis, and Chlamydia pneumoniae in infected HeLa 229 cells with MICs ranging from 0.016 to 0.063 μg/mL^[4].
Olamufloxacin (24 h) methanesulfonate potently inhibits growth of clinical Neisseria gonorrhoeae isolates, including those with quinolone resistance-associated alterations in GyrA and ParC^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Olamufloxacin (3.13-50 mg/kg; p.o.; twice daily; 3 days) methanesulfonate demonstrates activity against P. aeruginosa-induced UTI in mice^[1].
Olamufloxacin (50 mg/kg; p.o.; three times daily; 3 days) methanesulfonate effectively reduces lung bacterial burden in mice with Penicillin-resistant S. pneumoniae pneumonia^[3].
Olamufloxacin (0.625 mg/kg; p.o.; twice daily; 3 days) methanesulfonate demonstrates potent activity against H. influenzae respiratory tract infection in ICR mice^[3].
Olamufloxacin (5-10 mg/kg; p.o.; twice daily; 5 days) methanesulfonate exhibits in vivo efficacy in mice with Chlamydia psittaci-induced pneumonia^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

482.53

C₂₁H₂₇FN₄O₆S

167888-07-5

CS(=O)(O)=O.N[C@H]1C2(CC2)CN(C(C(C)=C3N(C4CC4)C=C5C(O)=O)=C(F)C(N)=C3C5=O)C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yoshizumi S, et al. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. J Antimicrob Chemother. 2001;48(1):137-140.

  [2]. Takahashi Y, et al. In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother. 1997;41(6):1326-1330.

  [3]. Yoshizumi S, et al. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Antimicrob Agents Chemother. 1998;42(4):785-788.

  [4]. Niki Y, et al. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. Antimicrob Agents Chemother. 1997;41(4):857-859.

  [5]. Deguchi T, et al. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC. J Antimicrob Chemother. 1997;40(3):437-439.